Telmisartan/hydrochlorothiazide: a new fixed dose combination
Authors:
- Michel BurnierMBMichel Burnier
- 1 May 2005
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 3 (3) , 375-386
Abstract
Many patients with hypertension require two or more antihypertensive drugs with complementary mechanisms of action to lower their blood pressure and attain the therapeutic goals specified in internationally accepted guidelines. Yet, these latter guidelines offer the choice of fixed dose combinations as possible first-step therapies. The angiotensin II type 1-receptor antagonist telmisartan and the diuretic hydrochlorothiazide are two antihypertensive agents that have a well-recognized clinical efficacy. Their combination was shown in randomized, controlled trials to be more effective than each agent alone in lowering blood pressure, due to a dual and synergistic mechanism. Indeed, combining telmisartan with hydrochlorothiazide enhances the antihypertensive efficacy of telmisartan in almost two-thirds of hypertensive patients with mild-to-moderate hypertension. The pharmacokinetics and -dynamics of the combination are similar to monotherapy, and the addition of hydrochlorothiazide to telmisartan does not modify the excellent tolerability profile of the drug.Keywords
This publication has 53 references indexed in Scilit:
- Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ–Modulating ActivityHypertension, 2004
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension, 2003
- Angiotensin II Receptor BlockadeHypertension, 2003
- Telmisartan/HydrochlorothiazideDrugs, 2003
- A New Fixed-Dose Combination for Added Blood Pressure Control: Telmisartan Plus HydrochlorothiazideJournal of International Medical Research, 2002
- Comparison of a Fixed-Dose Combination of 40 mg Telmisartan Plus 12.5 mg Hydrochlorothiazide With 40 mg Telmisartan in the Control of Mild to Moderate HypertensionAmerican Journal of Therapeutics, 2002
- In Vitro and in Vivo Characterization of the Activity of Telmisartan: An Insurmountable Angiotensin II Receptor AntagonistThe Journal of Pharmacology and Experimental Therapeutics, 2002
- TelmisartanDrugs, 2001
- Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin???angiotensin-system gene expression and cardiovascular functionsJournal Of Hypertension, 1995
- Fixed-Dose Combination Antihypertensive DrugsDrugs, 1994